deruxtecan

Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and a maleimide-GGFG peptide linker used in the synthesis of DS-8201 and U3-1402.

VcMMAE-Deruxtecan is a toxic molecular conjugate (Drug-Linker Conjugates for ADC) composed of a linker and cytotoxic agents MMAE (microtubule inhibitor) and Exatecan (DNA topoisomerase I inhibitor). This compound is employed in the synthesis of ADCs.

Deruxtecan-Eribulin is a Drug-Linker Conjugate for ADC comprised of a linker and two cytotoxic molecules: Exatecan (a DNA topoisomerase I inhibitor) and Eribulin (a microtubule inhibitor). This compound is utilized in the synthesis of ADCs.

Deruxtecan Analog 2 (example 9 P3), a Deruxtecan derivative, serves as an agent-linker conjugate integrating Camptothecin (CPT), a Topo I inhibitor active against colorectal, breast, lung, and ovarian cancers, with a distinct linker. This analog is employed in synthesizing anti-FGFR2 ADC [1].

Deruxtecan (1R) is a drug-linker conjugate for antibody-drug conjugates (ADC) [1].

Deruxtecan analog 2 (monoTFA), a homolog of Deruxtecan, consists of the antibody-drug conjugate (ADC) toxin derivative DX-8951 (Dxd) connected through an ADC linker [1].

Gly-Mal-GGFG-Deruxtecan 2-hydroxy propionamide is a conjugate of a camptothecin-derived drug and a linker utilized for Antibody-Drug Conjugates (ADC) [1].

Cys-MC-GGFG-Dxd is a conjugate of Cys and Deruxtecan. It serves as a linker-toxin structural unit in an antibody-drug conjugate (ADC) for attaching an antibody Cys residue to a cytotoxic drug. Cys-MC-GGFG-Dxd is applicable in cancer research.

Fmoc-Val-Phe-Boc serves as both a PROTAC linker and a maleimide-GGFG peptide linker. This compound is utilized in the synthesis of Deruxtecan.

Fmoc-Gly-Gly-(D-Phe)-Gly-CH2-O-CH2-Cbz is a PROTAC linker and a maleimide-GGFG peptide linker. It can be utilized for the synthesis of Deruxtecan.

Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is an ADC linker used in synthesizing drug-linker conjugates for ADCs, particularly for the creation of Deruxtecan, a potent drug-linker conjugate [1].

Fmoc-Gly-Gly-Phe-Gly-CH2-O-CH2-Gly-CH2-O-CH2-Cbz serves as an ADC linker utilized in crafting ADCs (such as Trastuzumab deruxtecan and U3-1402). This compound facilitates the attachment of cytotoxic drugs to antibody molecules, enhancing targeted therapy effectiveness.

MTT5, a toll-like receptor 7 (TLR7) agonist, can be conjugated with Deruxtecan to exert antitumor activity in HER2-positive solid tumors through tumor cell killing and immune activation.